Product Details
Apo-Gefitinib
Gefitinib250 mg
Tablet
DIN/PIN/NPN
02468050
Manufacturer
Apotex Inc.
Formulary Listing Date
2017-10-30
Unit Price
62.3050
Amount MOH Pays
62.3050
Coverage Status
Off-Formulary Interchangeable Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
L01EB01
Interchangeable Products
DIN/ PIN/ NPN | Brand name | Unit Price | Amount MOH pays |
---|---|---|---|
02487748 | Sandoz Gefitinib | 62.3050 | 62.3050 |
02491796 | Nat-Gefitinib | 62.3050 | 62.3050 |
02500663 | Jamp-Gefitinib | 62.3050 | 62.3050 |
02248676 | Iressa | 74.1063 | 62.3050 |
02468050 | Apo-Gefitinib | 62.3050 | 62.3050 |
LU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Oncology Drugs | Gefitinib
For the first line, monotherapy treatment of locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) in patients who have activating mutations of epidermal growth factor receptor-tyrosine kinase (EGFR-TK). (i.e. Patients who are EGFR Positive) The patient is to be assessed for disease status at least every two months and treatment will be discontinued if there is evidence of disease progression. Dose Reimbursed: 250 mg orally once daily. Duration of Approval: 6 months Iressa will not be granted funding in the following circumstances:
Patients who receive gefitinib (Iressa) first line are not eligible for erlotinib in the second- or third-line in the setting of maintenance therapy of NSCLC. Requests for gefitinib for patients who have initiated another EGFR TKI therapy (i.e., Afatanib [Giotrif]) in the first line setting and who have not had disease progression will be considered on a case-by-case basis. Renewal will be considered for patients until there is any evidence of disease progression, at which point, treatment with gefitinib (Iressa) must be discontinued. Patients must have their disease status assessed at least every two months. Dose Reimbursed: 250 mg orally once daily. Duration of Approval: 6 months EAP Drug Request Form: |